Hyderabad, July 24 -- In a landmark moment for India's biotechnology sector, Hyderabad-based biotech startup Tulsi Therapeutics, which focused on regenerative medicine using stem cells and exosomes, and ASPIRE-BioNEST, University of Hyderabad (UoH), today announced the world's first successful animal trial of a novel stem cell-exosome combination therapy for chronic liver failure.
The investigational product, Tulsi-28X, is a first-in-class regenerative therapy derived from Wharton's Jelly mesenchymal stem cells and their native exosomes-a combination never before tested in any animal model worldwide, the University said in a release here.
While conceptualized in the United States, the platform was entirely developed in India through three...